Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia B. WFH state-of-the-art session on therapeutic gene transfer Buenos Aires, Argentina

Haemophilia

Volumn 16, Issue SUPPL. 5, 2010, Pages 29-34

  Montgomery, R R ^a   Monahan, P E ^b   Ozelo, M C ^c  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Factor IX; Factor VIII; FVIII inhibitor; Gene therapy; Haemophilia A; Haemophilia B

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; DESMOPRESSIN; PARVOVIRUS VECTOR; VON WILLEBRAND FACTOR;

ARGENTINA; ARTHROPATHY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DRUG EFFICACY; EX VIVO STUDY; GENE THERAPY; GENE TRANSFER; HEMARTHROSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SYNOVITIS; TRANSGENE;

FACTOR IX; FACTOR VIII; FACTOR X; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELLS; HEMOPHILIA A; HEMOPHILIA B; HUMANS;

EID: 77955030405     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2010.02290.x     Document Type: Review

References (40)

1. Manno CS, Chew AJ, Hutchison S. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003, 101:2963-72.
2. Manno CS, Pierce GF, Arruda VR. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006, 12:342-7.
3. Roth DA, Tawa NE, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med 2001, 344:1735-42.
4. Powell JS, Ragni MV, White GC. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003, 102:2038-45.
5. Roosendaal G, Van Den Berg HM, Lafeber FP, Bjilsma J. Blood-induced joint damage: an overview of musculoskeletal research in haemophilia. Musculoskeletal Aspects of Haemophili 2000, 18. Rodriguez-Merchan EC, Goddard DR, Lee A, eds, Oxford, Blackwell Science
6. Evans CH, Ghivizzani SC, Robbins PD. Progress and prospects: genetic treatments for disorders of bones and joints. Gene Ther 2009, 16:944-52.
7. Madry H, Cucchiarini M, Terwilliger EF, Trippel SB. Recombinant adeno-associated virus vectors efficiently and persistently transduce chondrocytes in normal and osteoarthritic human articular cartilage. Hum Gene Ther 2003, 14:393-402.
8. Mease PJ, Wei N, Fudman EJ. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: results of a phase 1/2 study. J Rheumatol 2010, 37:692-703.
9. Roosendaal G, Lafeber FP. Pathogenesis of haemophilic arthropathy. Haemophilia 2006, 12(Suppl. 3):117-21.
10. Ponder KP. Gene therapy for hemophilia. Curr Opin Hematol 2006, 13:301-7.
11. Sun J, Hakobyan N, Valentino LA, Feldman BL, Samulski RJ, Monahan PE. Intraarticular factor IX protein or gene replacement protects against development of hemophilic synovitis in the absence of circulating factor IX. Blood 2008, 112:4532-41.
12. Sun J, Monahan PE. Extra-vascular clotting factor VIII protein protects agaionst development of haemophilic synovitis in the presence of pre-existing anti-factor VIII inhibitor. Haemophilia 2009, 15:634.
13. Valentino LA, Hakobyan N, Kazarian T, Jabbar KJ, Jabbar AA. Experimental haemophilic synovitis: rationale and development of a murine model of human factor VIII deficiency. Haemophilia 2004, 10:280-7.
14. Valentino LA, Hakobyan N. Histological changes in murine haemophilic synovitis: a quantitative grading system to assess blood-induced synovitis. Haemophilia 2006, 12:654-62.
15. Hakobyan N, Enockson C, Cole AA, Sumner DR, Valentino LA. Experimental haemophilic arthropathy in a mouse model of a massive haemarthrosis: gross, radiological and histological changes. Haemophilia 2008, 14:804-9.
16. Hoffman M. Animal models of bleeding and tissue repair. Haemophilia 2008, 14(Suppl. 3):62-7.
17. VandenDriessche T, Vanslembrouck V, Goovaerts I. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII- deficient mice. Proc Natl Acad Sci USA 1999, 96:10379-84.
18. Nathwani AC, Davidoff AM, Hanawa H. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 2002, 100:1662-9.
19. Mount JD, Herzog RW, Tillson DM. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002, 99:2670-6.
20. Chuah MK, Schiedner G, Thorrez L. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood 2003, 101:1734-43.
21. Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood 2004, 103:804-10.
22. Brown BD, Lillicrap D. Dangerous liaisons: the role of " danger" signals in the immune response to gene therapy. Blood 2002, 100:1133-40.
23. Mingozzi F, Maus MV, Hui DJ. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007, 13:419-22.
24. Moayeri M, Hawley TS, Hawley RG. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 2005, 12:1034-42.
25. Gangadharan B, Parker ET, Ide LM, Spencer HT, Doering CB. High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells. Blood 2006, 107:3859-64.
26. Yarovoi HV, Kufrin D, Eslin DE. Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. Blood 2003, 102:4006-13.
27. Shi Q, Wilcox DA, Fahs SA. Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 2006, 116:1974-82.
28. Du LM, Nichols AJ, Haberichter SA. Plateletitargeted expression of human BDD-FVIII reduces bleeding in canine hemophilia. Blood 2009, 114:289.
29. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002, 99:457-62.
30. Matsui H, Shibata M, Brown B. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells 2007, 25:2660-9.
31. Ozelo MC, Matsui H, Hegadorn CA. Genetically-engineered endothelial cells implanted into the omentum of hemophilia A dogs provides long-term circulating FVIII resulting from sustained FVIII expression and persistent cell viability. Blood 2009, 114:1386.
32. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 2006, 126:663-76.
33. Xu D, Alipio Z, Fink LM. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci USA 2009, 106:808-13. (PMCID: PMC2630078)
34. Tuddenham EG, Ingerslev J, Sorensen LN. Genetic aspects and research development in haemostasis. Haemophilia 2008, 14(Suppl. 3):113-8.
35. High KA. Update on progress and hurdles in novel genetic therapies for hemophilia. Hematology Am Soc Hematol Educ Program 2007, 466-72.
36. Montgomery RR, Gill JC. Interactions between von Willebrand factor and Factor VIII: where did they first meet? J Pediatr Hematol Oncol 2000, 22:269-75.
37. Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR. Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. Mol Genet Metab 2003, 79:25-33.
38. Rosenberg JB, Greengard JS, Montgomery RR. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 2000, 20:2689-95.
39. Shi Q, Wilcox DA, Fahs SA. Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. J Thromb Haemost 2007, 5:352-61.
40. Shi Q, Fahs SA, Wilcox DA. Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. Blood 2008, 112:2713-21.